Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Single-Arm, Open-Label Study to Assess the Safety and Efficacy of Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia - The CORAL Study

X
Trial Profile

A Phase 2 Single-Arm, Open-Label Study to Assess the Safety and Efficacy of Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia - The CORAL Study

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Venetoclax (Primary) ; Zandelisib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Acronyms CORAL; The CORAL Study
  • Sponsors MEI Pharma
  • Most Recent Events

    • 14 Mar 2023 Planned End Date changed from 1 Mar 2026 to 15 Mar 2023.
    • 14 Mar 2023 Planned primary completion date changed from 1 Mar 2024 to 15 Mar 2023.
    • 14 Mar 2023 Status changed from active, no longer recruiting to withdrawn prior to enrolment due to discontinuation of zandelisib development.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top